文献速递细菌感染、耐药与抗菌药物医院感染防控

深部标本嗜麦芽窄食单胞菌的管理与结局:双中心回顾性队列研究

Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该双中心回顾性队列纳入2018–2020年巴黎两家学术医院131例至少一次深部标本分离出嗜麦芽窄食单胞菌的患者,63%免疫抑制、31%入住ICU,28天死亡率为20%。倾向评分加权后,体外敏感指导的靶向治疗与28天死亡率改善无显著关联,机械通气与死亡率独立相关。

要点

  • 深部标本分离嗜麦芽窄食单胞菌者免疫抑制和重症比例高,28天死亡率20%。
  • 倾向评分加权后,体外敏感指导的靶向治疗未显著改善28天生存。
  • 机械通气与28天死亡率独立相关(HR 4.13,P=0.001)。

核心结论

  • 体外敏感指导的靶向治疗未显著降低深部标本嗜麦芽窄食单胞菌患者的28天死亡率,提示患者基础状况和感染严重程度可能超过靶向治疗本身的影响。

研究设计与样本

  • 双中心回顾性队列研究,纳入2018至2020年巴黎两家学术医院至少一次深部标本分离出嗜麦芽窄食单胞菌的全部患者,共131例(67%男性,中位年龄61岁)。

主要发现

  • 63%患者免疫抑制,31%入住ICU;标本主要来自尿液(41%)、血液(32%)和呼吸道(21%),57%培养为混合微生物。
  • 53%患者接受了适当治疗,以甲氧苄啶/磺胺甲噁唑或氟喹诺酮类为主。
  • 总体28天死亡率为20%。
  • 机械通气与死亡率独立相关(HR 4.13,P=0.001)。
  • 倾向评分加权后,适当治疗与28天生存改善无显著关联。

关键数值与推荐

  • 适当治疗依据体外药敏结果定义。
  • 采用倾向评分加权校正混杂因素后评估适当治疗与28天死亡率的关联。

临床怎么用

  • 在启动针对嗜麦芽窄食单胞菌的特异性治疗前,应仔细评估临床情况,区分感染与定植,尤其需考虑患者基础状况和感染严重程度。

局限性

  • 样本量有限,存在潜在混杂,且该分析为次要分析,结果应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Stenotrophomonas maltophilia is an emerging multidrug-resistant opportunistic pathogen, frequently recovered from deep sites in immunocompromised or critically ill patients. Its clinical relevance is difficult to distinguish from colonization, particularly in polymicrobial infections. To describe the management of patients with deep-site S. maltophilia isolates and to identify factors associated with 28-day mortality. METHODS: We conducted a bicentric retrospective study including all patients with at least one deep-site S. maltophilia isolates in two Paris academic hospitals between 2018 and 2020. Demographic, clinical, microbiological and therapeutic data were collected. Appropriate therapy was defined upon in vitro susceptibility. Propensity score weighting was applied to adjust for confounding when assessing the association between appropriate therapy and 28-day mortality. RESULTS: A total of 131 patients were included (67% male; median age 61 years); 63% were immunocompromised and 31% admitted to intensive care. Isolates originated mainly from urine (41%), blood (32%) and respiratory samples (21%); 57% of cultures were polymicrobial. Appropriate therapy was administered to 53% of patients, predominantly trimethoprim/sulfamethoxazole or fluoroquinolones. Overall 28-day mortality was 20%. Mechanical ventilation was independently associated with mortality (HR 4.13, P = 0.001). After propensity score weighting, appropriate therapy was not significantly associated with improved survival. CONCLUSION: Targeted therapy against S. maltophilia did not reduce 28-day mortality after adjustment, suggesting that patient condition and infection severity may outweigh the effect of targeted treatment. Given the modest sample size, potential confounding, and the secondary nature of this analysis, these findings should be interpreted with caution. Careful clinical evaluation is warranted before initiating specific S. maltophilia therapy.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Saade A, Pilmis B, Jacquier H, et al. Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study. J Antimicrob Chemother. 2026. PMID: 41631693. doi:10.1093/jac/dkag021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。